Focused On-demand Library for Sodium-dependent phosphate transport protein 2B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O95436

UPID:

NPT2B_HUMAN

Alternative names:

Na(+)-dependent phosphate cotransporter 2B; NaPi3b; Sodium/phosphate cotransporter 2B; Solute carrier family 34 member 2

Alternative UPACC:

O95436; A5PL17; Q8N2K2; Q8WYA9; Q9P0V7

Background:

Sodium-dependent phosphate transport protein 2B, also known as Na(+)-dependent phosphate cotransporter 2B, NaPi3b, and Solute carrier family 34 member 2, plays a crucial role in phosphate homeostasis by actively transporting phosphate into cells via Na(+) cotransport. This protein's function is vital for maintaining the balance of phosphate in the body, which is essential for various biological processes including bone formation and energy metabolism.

Therapeutic significance:

The protein is directly linked to Pulmonary alveolar microlithiasis, a rare disease characterized by calcium phosphate microliths depositing in the lungs, leading to progressive deterioration of lung functions. Understanding the role of Sodium-dependent phosphate transport protein 2B in this condition could pave the way for developing targeted therapies, potentially offering hope for patients suffering from this debilitating disease.